

For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

**UNITED THERAPEUTICS ENGAGES ERNST & YOUNG
AS INDEPENDENT PUBLIC ACCOUNTANTS**

Silver Spring, MD, September 8, 2003: United Therapeutics Corporation (NASDAQ:UTHR) announced today that the Audit Committee of its Board of Directors engaged Ernst & Young LLP as the company's independent public accountants, succeeding KPMG LLP.

"KPMG served as United Therapeutics' auditors since the company's inception," said R. Paul Gray, Chairman of the United Therapeutics Audit Committee. "While we have been satisfied with KPMG, the Audit Committee felt that a change in auditors after this many years is consistent with good corporate governance, just as the Sarbanes-Oxley Act now requires regular auditor personnel rotation. We look forward to working with the accomplished biotechnology audit professionals at Ernst & Young."

The Audit Committee's decision to change auditors was not the result of any disagreement between United Therapeutics and KPMG on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.